Spatially resolved determination of the abundance of the HER2 marker in microscopic breast tumors using targeted SERS imaging.
Mikrochim Acta
; 188(9): 288, 2021 08 05.
Article
en En
| MEDLINE
| ID: mdl-34350526
Highly selective nanoprobes have been developed based on SERS-active Au@Ag nanoparticles protected by a PEG coating and functionalized with monoclonal antibodies against human epidermal growth factor receptor 2 (HER2). The PEG coating allows to drastically reduce unspecific interactions during incubation on tissues, while the monoclonal antibodies allow a highly specific targeting of HER2. Using the designed SERS nanoprobes combined with a spectral imaging and data weighting approach, we demonstrate the proportionality between the SERS signal and the amount of HER2 antigen on the cell membranes as measured by digital image analysis of IHC staining in microscopic breast tumors (linear fit R2 = 0.87). We also show that the level of expression of HER2 measured by SERS is significantly different between several microscopic tumor parts of the same tissue slide. Therefore, SERS is proving to be a suitable technique for the localized quantitative measurement of specific markers in breast cancerous tissues. Owing to its high multiplexing capabilities, SERS could be a future tool of choice for characterizing the molecular heterogeneity of tumors at the microscopic scale.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Espectrometría Raman
/
Neoplasias de la Mama
/
Biomarcadores de Tumor
/
Receptor ErbB-2
/
Nanopartículas del Metal
Límite:
Female
/
Humans
Idioma:
En
Revista:
Mikrochim Acta
Año:
2021
Tipo del documento:
Article
País de afiliación:
Bélgica
Pais de publicación:
Austria